![](/images/graphics-bg.png)
Validation of Serum Biomarkers Derived from Proteomic Analysis for the Early Screening of Preeclampsia
المؤلفون المشاركون
Kolialexi, Aggeliki
Gourgiotis, Dimitrios
Daskalakis, George
Marmarinos, Antonis
Lykoudi, Alexandra
Mavreli, Danai
Mavrou, Ariadni
Papantoniou, Nikolas
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-01-05
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Aim.
To examine the potential value of previously identified biomarkers using proteomics in early screening for preeclampsia (PE).
Methods.
24 blood samples from women who subsequently developed PE and 48 from uncomplicated pregnancies were obtained at 11–13 weeks and analysed after delivery.
Cystatin-C, sVCAM-1, and Pappalysin-1 were quantified by ELISA.
Maternal characteristics and medical history were recorded.
Results.
Median values of Cystatin-C, sVCAM-1, and Pappalysin-1 in the PE group as compared to controls were 909.1 gEq/mL versus 480.0 gEq/mL, P = .
000 , 832.0 gEq/mL versus 738.8 gEq/mL, P = .
024 , and 234.4 gEq/mL versus 74.9 gEq/mL, P = .
064 , respectively.
Areas under the receiver-operating characteristic curves (AUC, standard error (SE)) for predicting PE were Cystatin-C: 0.90 (SE 0.04), VCAM-1: 0.66 (SE 0.074), and Pappalysin-1: 0.63 (SE 0.083).
To discriminate between cases at risk for PE and normal controls, cut-off values of 546.8 gEq/mL for Cystatin-C, 1059.5 gEq/mL for sVCAM-1, and 220.8 gEq/mL for Pappalysin-1 were chosen, providing sensitivity of 91%, 41%, and 54% and specificity of 85%, 100%, and 95%, respectively.
Conclusions.
sVCAM-1 and Pappalysin-1 do not improve early screening for PE.
Cystatin-C, however, seems to be associated with subsequent PE development, but larger studies are necessary to validate these findings.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Kolialexi, Aggeliki& Gourgiotis, Dimitrios& Daskalakis, George& Marmarinos, Antonis& Lykoudi, Alexandra& Mavreli, Danai…[et al.]. 2015. Validation of Serum Biomarkers Derived from Proteomic Analysis for the Early Screening of Preeclampsia. Disease Markers،Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1060854
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Kolialexi, Aggeliki…[et al.]. Validation of Serum Biomarkers Derived from Proteomic Analysis for the Early Screening of Preeclampsia. Disease Markers No. 2015 (2015), pp.1-7.
https://search.emarefa.net/detail/BIM-1060854
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Kolialexi, Aggeliki& Gourgiotis, Dimitrios& Daskalakis, George& Marmarinos, Antonis& Lykoudi, Alexandra& Mavreli, Danai…[et al.]. Validation of Serum Biomarkers Derived from Proteomic Analysis for the Early Screening of Preeclampsia. Disease Markers. 2015. Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1060854
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1060854
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)